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Clinical Case Report and Review
ABSTRACT
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCOGCs) is an extremely rare morphologically 
and clinically distinct variant of pancreatic ductal adenocarcinoma (PDAC), exhibiting a characteristic component of reactive 
osteoclast-like giant cells admixed with neoplastic mononuclear cells. Sommers and Meissner first described it in 1954 
as an “unusual carcinoma of the pancreas”. Later it acquired many different names. In 2010, the WHO classified these 
tumors as a variant of PDAC under the heading of “undifferentiated carcinoma with osteoclast-like giant cells”. Here we 
describe the first case of pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) composed of UCOGC 
and pancreatic neuroendocrine tumor (NET), which occurred in a 78-year-old man with biliary colic and pancreatitis. 
The mass did not respond to the chemotherapy, and he soon developed liver metastasis from the NET component, and 
unfortunately, the patient passed away 10 months later. Since UCOGC is extremely rare, and its association with NET 
has not been reported yet, our case expands the knowledge regarding its unusual presentation and poor prognosis. 
Keywords  
Pancreatic Neoplasms, Ductal Carcinoma of the Pancreas, Neuroendocrine Tumors, Carcinomas.
INTRODUCTION
Pancreatic cancer is among the most devastating 
and lethal of all cancers. It comprises just 3 percent 
of all cancer cases in the United States, but its 
incidence is increasing. Some studies estimated the 
pancreatic cancer to become the second leading 
cause of cancer-related death by 2030.1 More than 
55,000 Americans are estimated to be diagnosed 
with pancreatic cancer in 2018 (3.2% of all new 
cancers, 11th most common cancer with a roughly 
equal gender predilection). However, due to the 
dismal 5-year survival rate (less than 9%), more than 
44,000 will die from the disease in 2018 (7.3 percent 
of all cancer deaths), which makes it, currently, 
the third leading cause of cancer-related deaths in 
the United States.2 The vast majority of pancreatic 
cancers are pancreatic ductal adenocarcinoma 
(PDAC), an invasive mucin-producing gland-forming 
neoplasm with common somatic mutations involving 
KRAS oncogenes and TP53, CDKN2A, and SMAD4 
tumor suppressors.3
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Undifferentiated carcinoma of the pancreas with 
osteoclast-like giant cells (UCOGCs) is an extremely 
rare variant of PDAC with an incidence of less than 
1% of all pancreatic tumors.4 It was first described by 
Sommers and Meissner5:101-111 in 1954 as an 
“unusual carcinoma of the pancreas”. Later, 
it acquired many different names, like “carcinomas 
of pancreas simulating giant cell tumor of bone”, 
“osteoclastic giant cell tumor or carcinoma,” and 
“pleomorphic carcinoma of the pancreas, giant cell 
carcinoma”. In 2010, the World Health Organization 
classified these tumors as a variant of PDAC under 
the heading “ undifferentiated carcinoma with 
osteoclast-like giant cells.”6 These tumors have a 
characteristic morphology consisting of neoplastic 
mononuclear cells, some with significant cytologic 
atypia, admixed with reactive large multinucleated 
osteoclast- l ike giant cel ls .  The nucle i  of the 
osteoclast-like giant cells are uniform. Some of the 
osteoclast-like giant cells are actively phagocytic. 
Despite their unique morphologic features, they have 
strikingly similar mutations to PDACs.7,8 Tumors of 
UCOGCs are typically large (several centimeters) and 
may exhibit polypoid intraductal or intra-ampullary 
growth, or cystic degeneration. They may arise in 
mucinous cystic neoplasm or intraductal papillary 
mucinous neoplasm.9,10 The mean age of patients with 
UCOGCs is 62 years, with an equal male to female 
ratio, and mean survival rate of 12 months.6,11
UCOGC, is characterized by undifferentiated/
anaplastic malignant cells, mixed with nonneoplastic 
osteoclast-like giant cells. Although the histopathological 
hallmark of UCOGCs is the characteristic large, bland, 
multinucleated osteoclast-like giant cells, these cells are 
not neoplastic. Morphologic, immunohistochemical, 
molecu lar ,  and u l t ras t ructura l  s tud ies  have 
demonstrated that they represent benign histiocytic 
cells likely recruited by chemotactic substances of the 
tumoral cells. They show phagocytic capability (may 
contain neoplastic cells engulfed in the cytoplasm) 
and express histiocytic markers (CD68, vimentin, and 
common leukocyte antigen (CD45), but not keratin). 
They also have wild type p53 staining pattern on IHC. 
Mononuclear neoplastic cells usually do not show 
any line of differentiation on immunohistochemistry 
studies, but some show epithelial differentiation 
by expressing cytokeratin and diffuse positive for 
p53 (mutant p53 staining pattern). Ultrastructural 
findings of these mononuclear cells may reveal 
epithelial differentiation (desmosomes, microvilli, and 
zymogen-like granules). Tumors may exhibit extensive 
fibrosis, hemorrhage, and even osteoid formation, 
which may lead to a nondiagnostic sample; therefore, 
careful cytologic examination and histologic sampling 
are important.6,12
Cytological examinations of fine-needle aspiration 
are typically hypercellular, composed of highly 
characteristic multinucleated osteoclast-like giant cells 
intermingled with a noncohesive round to spindled 
cells and pleomorphic, hyperchromatic nuclei, and 
prominent nucleoli.13
It is being described that many tumors of 
undifferentiated carcinomas with osteoclast-like 
giant cells contain a separate glandular component 
or are associated with a preinvasive neoplasm, such 
as a mucinous cystic neoplasm.6,7,9,10 However, up to 
this date, no possible association with neuroendocrine 
neoplasm (NET or NEC) component has been 
reported in patients with UCOCG. A review of the 
English-speaking literature was performed by the 
authors, using the PubMed database by searching the 
terms “undifferentiated carcinoma with osteoclastic 
giant cells of the pancreas”, and none of the reported 
UCOCGs was found to have a NET component.
Pancreatic endocrine neoplasms (PENs) are rare and 
account for approximately 2% of all pancreatic neoplasms. 
They are epithelial tumors with endocrine differentiation, 
commonly affect adults between 30 to 60 years of age 
with no sex predilection.6 Microscopically, these tumors 
are composed of uniform cuboidal cells with centrally 
located nuclei and finely granular cytoplasm arranged in 
nests or tubules. They can be functional (gastrinomas, 
glucagonomas, etc.) or nonfunctional. They may be 
present sporadically or related to a familial syndrome 
(such as multiple endocrine neoplasia, also known as MEN 
syndromes). Immunohistochemically, Synaptophysin, 
and Chromogranin A may be useful in confirming the 
diagnosis. They also can express CD56, PAX8, and CK7. 
The molecular genetics of Pancreas NETs differ significantly 
from those of pancreatic ductal adenocarcinoma. 
Pancreas NETs do not typically have mutations in KRAS, 
CDKN2A, or SMAD4, and only a small minority harbor 
TP53 mutations.14 One of the most challenging aspects 
of these tumors is the prediction of their biologic 
behavior. The mitotic count and Ki-67 proliferation 
index seems to be the most important factor that 
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correlates with prognosis. The 2019 WHO classification 
of neuroendocrine neoplasms of the gastrointestinal 
tract and hepatobiliary organs classifies the pancreatic 
neuroendocrine neoplasms into G1 NET (low grade 
well-differentiated, mitoses <2/10HPF and Ki67 index 
<3%); G2 NET (intermediate grade well-differentiated, 
mitoses 2–20/10/HPF or Ki67 index 3%–20%); G3 NET 
(high grade well-differentiated, mitoses >20/10HPF 
or Ki67 index >20%); neuroendocrine carcinoma 
(poorly-differentiated, mitoses >20/10HPF or Ki67 index 
>20%, including small cell type and large-cell type); 
and MiENE (mixed neuroendocrine-nonneuroendocrine 
neoplasm).6
Pancreatic MiNENs are neoplasms composed 
of morphologically recognizable neuroendocrine 
and non-neuroendocrine components. Mixed 
ductal-neuroendocrine carcinomas account for about 
0.5-2% of all ductal adenocarcinoma and usually 
metastasize to lymph nodes and liver.6 MiNENs 
include a range of specific diagnostic entities in the 
pancreas. Here we report the first case of pancreatic 
MiNEN of undifferentiated pancreatic carcinoma with 
osteoclast-like giant cells and neuroendocrine tumor 
with metastatic neuroendocrine component to the Liver.
Case Report
A 78-year-old man with a history of biliary colic 
presented with abdominal pain. The abdominal axial 
computed tomography (CT) scan showed a 0.7 cm 
hypodense lesion in the pancreas (Figure 1).
Endoscopic ultrasound (EUS) demonstrated a mass 
in the uncinate process of the pancreas. EUS-guided 
transduodenal fine needle aspiration (FNA) of the mass 
was performed.
Smears by Diff-Quik stain and Papanicolaou stain 
were hypercellular and showed large tumor cells as 
crowded clusters, syncytial groups and singly dispersed, 
which were composed of three different types of cells: 
pleomorphic hyperchromatic tumor cells with irregular 
nuclear contours; multinuclear osteoclastic giant cells 
with smooth nuclear membranes, pale chromatin, 
and moderate cytoplasm; and some spindle-shaped 
tumor cells with slightly enlarged round to oval 
nuclei, irregular nuclear membranes, and moderate 
cytoplasm (Figures 2A, 2B). H&E sections from the 
cell bock showed similar morphologic features 
(Figure 2C). The immunohistochemistry study on 
the cellblock showed three different components 
(Table 1). The majority of tumor cells were diffusely 
and strongly positive for CK AE1/AE3, and p53, 
but negative for CD68, SMAD4, CK20, Glypican-3, 
CD56, Synaptophysin, TTF1, CA19-9, and HepPar1. 
Scattered osteoclast giant cells were noted, which were 
negative for epithelial markers (AE1/AE3, p53) but 
positive for CD68. A minor component of coexisting 
neuroendocrine neoplasm (<5%) was also noted, 
supported by different cytomorphology and different 
immunohistochemical stain pattern (small tumor 
cells positive for CK7, synaptophysin, CK19, CA19-9, 
SMAD4, CK AE1/AE3, and CD56; negative for 
Glypican-3, HEP PAR1, CK20, CD68, and PSA) 
(Figures 2D, 3A-3D, and 4A-4D). The paucity of 
these neuroendocrine cells precluded the evaluation 
proliferation index by Ki67 immunostaining (it was 
observed as less than 20%).
While the patient was waiting for chemotherapy, 
an abdominal magnetic resonance imaging (MRI) 
showed a marked increase in the size of pancreatic mass 
with multiple small enhancing liver lesions. EUS-guided 
FNA of the liver mass revealed a neuroendocrine tumor 
composed of cells with similar cytomorphological 
features to the above neuroendocrine component 
of UCOGCs, supported by Immunohistochemical 
stains (positive for synaptophysin, CD56, and 
CK AE1/AE3; negative for HEP PAR1, Glypican-3, 
and CD45) (Figures 5A-D). Ki-67 proliferation index 
was approximately 30-40%. The patient initially 
Figure 1. Abdominal axial computed tomography (CT) 
scan shows a 0.7 cm hypodense mass in the pancreas 
(arrow).
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received chemotherapy (paclitaxel plus gemcitabine 
combination), which he tolerated poorly. Therefore, 
paclitaxel was discontinued and he was resumed 
chemotherapy with gemcitabine alone. Unfortunately, 
he passed away 10 months after his initial diagnosis 
of UCOGCs.
DISCUSSION
P a n c r e a t i c  m i x e d  n e u r o e n d o c r i n e -
nonneuroendocrine neoplasm (MiNEN) includes a 
range of specific diagnostic entities in the pancreas. 
Here we report the first case of pancreatic MiNEN 
Figure 2. Photomicrographs of endoscopic ultrasound (EUS)-guided fine-needle aspiration biopsy (FNA) of the 
pancreas mass (400 x magnification); A – Diff-quick-stained smear showing hypercellular smear consists of 
pleomorphic tumor cells and osteoclast-like giant cells; B – Papanicolaou-stained smear showing hypercellular smear 
consists of cohesive spindle to pleomorphic tumor cells and osteoclast-like giant cells; C – H&E section of the cell 
block show pleomorphic and spindle cell neoplasm with scattered osteoclast giant cells (UCOGC component). 
Foci of smaller neoplastic round to spindle cells with scant finely granular cytoplasm and “salt and pepper” (finely 
stippled) chromatin are noted (neuroendocrine component; arrow); D – AE1/AE3 immunostain.
Table 1. Histological and immunohistochemical patterns on the cell block
Component AE1/AE3 P53 CD68 CK7 CK19 Syn SMAD4 CD56 CK20 CA19-9
Pleomorphic cells + + - +/- +/- - - - - -
Osteoclast-like giant cells - - + - - - - - - -
Neuroendocrine cells + Weak/- - + + + + + - +
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Figure 3. Photomicrographs of endoscopic ultrasound (EUS)-guided fine-needle aspiration biopsy (FNA) of the 
pancreas mass (400 x magnification), arrow indicates neuroendocrine component and the remaining cells are 
UCOGC component; A – P53 immunostain; B – CD68 immunostain; C – CK7 immunostain; D – CK19 immunostain.
of undifferentiated pancreatic carcinoma with 
osteoclast-like giant cells and neuroendocrine tumor 
with metastatic neuroendocrine component to the 
Liver.
Pancreatic undifferentiated carcinomas with 
osteoclast-like giant cells are currently considered 
as a distinct and rare variant of pancreatic ductal 
adenocarcinoma (PDAC), which was supported by 
their shared strikingly similar genetic alterations 
known to drive carcinogenesis, including activating 
mutations in the oncogene KRAS and inactivating 
mutations in the tumor suppressor genes CDKN2A, 
TP53 ,  and SMAD4 . 7 The study of a ser ies of 
22 UCOGCs by Luchini et al.7 showed that only one 
non‐synonymous missense mutation was identified in 
SMAD4 in one of eight UCOGCs with whole exome 
sequencing (WES) analysis, and approximately half 
(9) of 19 UCOGCs had loss of SMAD4 expression on 
formalin-fixed paraphing-embedded (FFPE) sections 
by immunohistochemistry, including the case with 
somatic mutation identified by WES and two other 
cases with likely homozygous deletions. Five other 
UCOGCs analyzed by WES were demonstrated 
as SMAD4 wild‑type and had intact expression. 
A study by Tang et al.15 demonstrated that abnormal 
p53, Rb, or SMAD4 expression in 11/33 cases of 
poorly differentiated NECs. Waddell et al.16 showed 
that PDAC almost all have KRAS mutations, and 
Hijioka et al.17 demonstrated that 6 of their 7 cases 
of poorly differentiated NECs (86%) had KRAS 
mutations. These studies suggest that pNEC and PDAC 
have genetic similarities and may share a common 
origin.18 These suggest that somatic mutations may 
not be the determinants of the unique phenotype 
of PDACs, UCOGCs, or NECs. However, it has been 
demonstrated that pancreatic NECs often show 
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abnormal expression of p53 and RB1, but retain 
expression of DAXX and ATRX, while pancreatic G3 
NETs almost always have intact TP53 (only occasionally 
mutated in G3 PanNET with metastatic progression) 
and RB1, and lose DAXX and ATRX in approximately 
half cases, similar to low grade (G1-G2) pancreatic 
NET,15 suggesting that pancreatic NECs do not derive 
from pancreatic NET.
In general, undifferentiated carcinomas follow a 
more aggressive behavior, but some studies showed that 
undifferentiated pancreatic carcinoma with osteoclast-
like giant cells (UCOCGs) seems to predict improved 
prognosis. These findings, along with the presence of 
reactive OCGs in these tumors, raises the possibility that 
these OCGs are the result of the immune response that 
eliminates the PDAC component and results in improved 
prognosis. This hypothesis is further supported by 
observing the better prognosis in patients with UCOGC 
without PD-L1 expression.8 Muraki et al.19 reviewed 
38 cases of UCOCGs and showed that its survival rate 
is significantly better than that of PDAC (UCOCGs 
estimated 5-year survival rate of 59.1%). They also 
observed that 76% of UCOCGs had an invasive ductal 
component (PDACs), and 21% arose in an intraepithelial 
neoplasm (IPMN or MCN). However, to our best 
knowledge, the presence of a neuroendocrine neoplasm 
component (NET or NEC) has not been reported in 
patients with UCOCGs. Our patient is the first case of 
MiNEN composed of UCOCGs and NET component 
without having any observed ductal differentiation and 
with metastasis to the liver of the NET component.6 
Despite a possible better prognosis suggested by the 
study by Muraki et al.19 for patients of UCOCGs without 
ductal differentiation, according to WHO, resectability 
Figure 4. Photomicrographs of endoscopic ultrasound (EUS)-guided fine-needle aspiration biopsy (FNA) of 
the pancreas mass (400 x magnification) arrow indicates neuroendocrine component and the remaining cells 
are UCOGC component; A – Synaptophysin immunostain; B – SMAD4 immunostain; C – CD56 immunostain; 
D – CA19-9 immunostain.
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of the carcinoma is the most important prognostic 
factor for MiNEN and patients rarely survive > 3 years. 
The 2-year and 5-year survival rates are 25% and 
0%, respectively, although a study by Basturk et al.20 
suggested mixed ductal-neuroendocrine carcinomas 
have a slightly longer median survival time than pure 
NECs. Unfortunately, despite chemotherapy, our patient 
died within 10 months of initial diagnosis, due to the 
aggressive clinical course of the neuroendocrine tumor 
component.
Pancreatic MiNENs include a range of specific 
diagnostic entities in the pancreas and is composed 
of morphologically recognizable neuroendocrine and 
non-neuroendocrine components. The neuroendocrine 
component can be neuroendocrine tumor or 
neuroendocrine carcinoma.6 In this case report, we 
reported the first pancreatic MiNEN with UCOCGs 
and neuroendocrine components with metastatic 
neuroendocrine to the liver; the two components 
demonstrated different histology and immunostain 
profiles (Table 1).
The UCOCGs tumor cells were diffusely and 
strongly positive for CK AE1/AE3, p53 (diffuse 
strong), and lost expression of SMAD4; but negative 
for CK20, Glypican-3, CD56, Synaptophysin, TTF1, 
CA19-9, and HepPar1. The minor component of 
neuroendocrine tumor cells (<5%) were positive 
for CK7, synaptophysin, CK19, CA19-9, SMAD4, 
CK AE1/AE3, and CD56; but negative for Glypican-3, 
HEP PAR1, CK20, CD68, and PSA) (Figures 2-4). 
Figure 5. Photomicrography of endoscopic ultrasound (EUS)-guided fine-needle aspiration biopsy (FNA) of liver mass 
(400 x magnification), arrow indicates neuroendocrine component and the remaining cells are UCOGC component; 
A – Diff-quick-stained smear showing hypercellular smear consists of pleomorphic tumor cells with round to spindle 
nuclei, finely stippled chromatin, and scant cytoplasm; B – Papanicolaou-stained smear; C – Synaptophysin immunostain 
on the cell block show positive staining in neoplastic cells and negative staining in hepatic cells; D – CD56 immunostain 
on the cell block show positive staining in neoplastic cells and negative staining in hepatic cells.
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The neuroendocrine tumor cells were scarce and 
showed a Ki-67 proliferation index < 20%. Primary 
G3 PanNETs retain a well-differentiated histology, 
with characteristically “organoid” arrangements of 
the tumor cells (relatively uniform, round to oval 
nuclei, coarsely stippled chromatin, and finely granular 
cytoplasm) with solid/nesting, trabecular, gyriform, 
or sometimes glandular patterns. They have a Ki-67 
proliferation index > 20% and usually < 55%; however, 
no upper limit has been defined for their mitotic index 
or the Ki-67 proliferation index. They almost always 
have intact TP53 and RB1, and only occasionally, a 
G3 PanNET can develop a TP53 mutation during its 
metastatic progression. PanNET may contain low-grade 
components (G1, G2), or may present as metastases. 
Uniquely, the neuroendocrine component of our 
reported case of MiNEN (NET and UCOGCs) showed 
metastasis of the neuroendocrine tumor component 
to the liver. On the other hand, pancreatic NECs have 
poorly differentiated histology (either small cell or 
large cell type), tumor cells of irregular hyperchromatic 
nuclei growing in sheets, or diffuse architecture, often 
with large confluent areas of necrosis. The small cell 
type NECs consist of small- to medium-sized, round 
to oval cells with scant cytoplasm and hyperchromatic 
nuclei with indistinct nucleoli. The large-cell type 
NEC is composed of large cells with vesicular nuclei 
showing prominent nucleoli and abundant eosinophilic 
cytoplasm. However, histologically, morphological 
features may not always be reliable in separating a 
well-differentiated NET from a poorly-differentiated 
NEC. Furthermore, there is no Ki-67 index cutoff to 
separate G3 NET and NEC (both > 20%), although 
an extremely high Ki-67 proliferation index (>75%) 
or a mitotic rate > 20 per 10 HPFs usually indicates 
a NEC. Pancreatic NECs often show abnormal 
expression of p53 and RB1, but retain expression 
of DAXX and ATRX, which is lost in approximately 
half of pancreatic G3 NET cases, similar to low grade 
(G1-G2) pancreatic NET.15 According to the WHO, 
the histological classification of collision tumors 
include at least two different malignant components 
located in the same organ or anatomic site, without 
mixed or transitional area.6 Pancreatic collision tumors 
composed of both a neuroendocrine tumor and a ductal 
adenocarcinoma has been reported.21,22 However, to 
our knowledge, there is no reported case of a collision 
tumor of UCOGC with pancreatic NEN. Because we 
do not have a surgical biopsy or resection specimen 
to determine the transitional area or stroma between 
the two components, a collision tumor of UCOGC 
with pancreatic NEN cannot be ruled out. A diagnosis 
of UCOGC with neuroendocrine differentiation is not 
likely due to the different histological features and 
immunohistochemical profiles of the two components.
CONCLUSION
Pancreatic undifferentiated carcinomas with 
osteoclast-like giant cells are a distinct entity. 
An extensive histological sampling of UCOGCs is 
important to exclude associated PDAC or high-grade 
neuroendocrine carcinoma, which significantly impacts 
prognosis. Our reported case was the first reported 
incidence of a pancreatic MiNENs of undifferentiated 
pancreatic carcinoma with osteoclast-like giant 
cells and neuroendocrine tumor with metastatic 
neuroendocrine component to the liver, which 
expanded our knowledge regarding the clinical 
prognosis of this rare entity.
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